NYSE:TDOC

Teladoc Health Stock Forecast, Price & News

Followed 170 Times

$246.74

+14.02 (+6.02 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$234.20

Now: $246.74▼

$252.08

50-Day Range

$187.07

MA: $207.61▼

$232.72

52-Week Range

$93.56

Now: $246.74▼

$253.00

Volume6.36 million shs

Average Volume3.38 million shs

Market Capitalization$35.77 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.3

Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, expert medical services, behavioral health solutions, guidance and support, and platform and program services. The company's platform enables patients and providers to have an integrated smart user experience through mobile, Web, and phone based accessed points. 0It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies. Teladoc Health, Inc. offers its products and services under the Teladoc, Advance Medical, Best Doctors, BetterHelp, and HealthiestYou brands. Teladoc Health, Inc. has alliance with NTT DATA Services to build nucleus for healthcare. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was founded in 2002 and is headquartered in Purchase, New York.

MarketRank^™

Overall MarketRank^™

1.29 out of 5 stars

Medical Sector

703rd out of 1,928 stocks

Offices & Clinics Of Medical Doctors Industry

2nd out of 8 stocks

2.3 Analyst's Opinion

Consensus Rating
Teladoc Health has received a consensus rating of Buy. The company's average rating score is 2.59, and is based on 17 buy ratings, 12 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $236.23, Teladoc Health has a forecasted downside of 4.3% from its current price of $246.74.
Amount of Analyst Coverage
Teladoc Health has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Teladoc Health has received 584 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Teladoc Health has received 517 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Teladoc Health has received 53.04% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Teladoc Health and other stocks. Vote “Outperform” if you believe TDOC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Teladoc Health does not currently pay a dividend.
Dividend Growth
Teladoc Health does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Teladoc Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,265,594.00 in company stock.
Percentage Held by Insiders
Only 3.42% of the stock of Teladoc Health is held by insiders.
Percentage Held by Institutions
51.77% of the stock of Teladoc Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Teladoc Health are expected to grow in the coming year, from ($1.12) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Teladoc Health is -172.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Teladoc Health is -172.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Teladoc Health has a P/B Ratio of 17.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Offices & clinics of medical doctors

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:TDOC

Previous Symbol

CUSIPN/A

CIK1477449

Webwww.teladochealth.com

Phone203-635-2002

Employees2,400

Debt

Debt-to-Equity Ratio0.43

Current Ratio6.52

Quick Ratio6.47

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$553.31 million

Price / Sales64.64

Cash FlowN/A

Price / Cash FlowN/A

Book Value$14.01 per share

Price / Book17.61

Profitability

EPS (Most Recent Fiscal Year)($1.49)

Net Income$-98,860,000.00

Net Margins-12.71%

Return on Equity-6.15%

Return on Assets-3.75%

Miscellaneous

Outstanding Shares144,961,000

Market Cap$35.77 billion

Next Earnings Date2/24/2021 (Estimated)

OptionableOptionable

$246.74

+14.02 (+6.02 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TDOC News and Ratings via Email

Sign-up to receive the latest news and ratings for TDOC and its competitors with MarketBeat's FREE daily newsletter.

Teladoc Health (NYSE:TDOC) Frequently Asked Questions

How has Teladoc Health's stock price been impacted by Coronavirus (COVID-19)?

Teladoc Health's stock was trading at $137.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TDOC shares have increased by 79.6% and is now trading at $246.74.
View which stocks have been most impacted by COVID-19.

Is Teladoc Health a buy right now?

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last twelve months. There are currently 12 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Teladoc Health stock.
View analyst ratings for Teladoc Health or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Teladoc Health?

Wall Street analysts have given Teladoc Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Teladoc Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as Teladoc Health's CEO?

538 employees have rated Teladoc Health CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Teladoc Health's employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Teladoc Health's next earnings date?

Teladoc Health is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Teladoc Health.

How were Teladoc Health's earnings last quarter?

Teladoc Health, Inc. (NYSE:TDOC) issued its earnings results on Wednesday, October, 28th. The health services provider reported ($0.43) EPS for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.10. The health services provider had revenue of $288.81 million for the quarter, compared to the consensus estimate of $281.54 million. Teladoc Health had a negative return on equity of 6.15% and a negative net margin of 12.71%.
View Teladoc Health's earnings history.

What guidance has Teladoc Health issued on next quarter's earnings?

Teladoc Health issued an update on its fourth quarter 2020 After-Hours earnings guidance on Tuesday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $369-379 million, compared to the consensus revenue estimate of $347.16 million.

What price target have analysts set for TDOC?

29 analysts have issued twelve-month price targets for Teladoc Health's shares. Their forecasts range from $165.00 to $305.00. On average, they expect Teladoc Health's share price to reach $236.23 in the next twelve months. This suggests that the stock has a possible downside of 4.3%.
View analysts' price targets for Teladoc Health or view Wall Street analyst' top-rated stocks.

Who are some of Teladoc Health's key competitors?

Some companies that are related to Teladoc Health include AstraZeneca (AZN), Sanofi (SNY), AstraZeneca PLC (AZN.L) (AZN), CSL (CSLLY), GlaxoSmithKline (GSK), Intuitive Surgical (ISRG), Stryker (SYK), Gilead Sciences (GILD), Anthem (ANTM), Zoetis (ZTS), Becton, Dickinson and (BDX), GlaxoSmithKline plc (GSK.L) (GSK), Vertex Pharmaceuticals (VRTX), Bayer Aktiengesellschaft (BAYRY) and Illumina (ILMN).
View all of TDOC's competitors.

What other stocks do shareholders of Teladoc Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Square (SQ), Shopify (SHOP), DocuSign (DOCU), salesforce.com (CRM), PayPal (PYPL) and Zoom Video Communications (ZM).

Who are Teladoc Health's key executives?

Teladoc Health's management team includes the following people:

Mr. Jason Nathanial Gorevic, CEO & Director (Age 48, Pay $1.2M)
Ms. Mala Murthy, Chief Financial Officer (Age 56, Pay $647.34k)
Mr. David William Sides, Chief Operating Officer (Age 49, Pay $927.41k)
Mr. Adam Christian Vandervoort, Chief Legal Officer & Sec. (Age 45, Pay $541k)
Ms. Stephany Verstraete, Chief Marketing Officer & Engagement Officer (Age 51, Pay $503.37k)
Mr. Gabriel Raymond Cappucci CPA, CPA, Sr. VP of Fin. (Age 57, Pay $425.5k)
Dr. George Byron Brooks, Co-Founder
Mr. Patrick Thomas Feeley C.F.A., CPA, CPA, CFA, VP of Investor Relations
Ms. Courtney Kraemer McLeod, Director of Communication
Mr. Andrew Turitz, Sr. VP of Corp. Devel. (Age 47)

When did Teladoc Health IPO?

(TDOC) raised $112 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Teladoc Health's stock symbol?

Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Who are Teladoc Health's major shareholders?

Teladoc Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Ardevora Asset Management LLP (0.17%), Peregrine Capital Management LLC (0.13%), Spence Asset Management (0.09%), Rhenman & Partners Asset Management AB (0.08%), Bainco International Investors (0.04%) and Kestra Advisory Services LLC (0.02%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Gabriel R Cappucci, Glen Tullman, Hemant Taneja, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen, Stephany Verstraete, William H Frist and Yulun Wang.
View institutional ownership trends for Teladoc Health.

Which major investors are selling Teladoc Health stock?

TDOC stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors, Meridian Wealth Management LLC, Traynor Capital Management Inc., First Citizens Bank & Trust Co., Sowell Financial Services LLC, Raymond James Trust N.A., ProVise Management Group LLC, and Brookstone Capital Management. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Gabriel R Cappucci, Glen Tullman, Hemant Taneja, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Stephany Verstraete, William H Frist, and Yulun Wang.
View insider buying and selling activity for Teladoc Health or view top insider-selling stocks.

Which major investors are buying Teladoc Health stock?

TDOC stock was purchased by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Spence Asset Management, Rhenman & Partners Asset Management AB, Hamilton Lane Advisors LLC, Peregrine Capital Management LLC, Kestra Advisory Services LLC, DNB Asset Management AS, and Tributary Capital Management LLC.
View insider buying and selling activity for Teladoc Health or or view top insider-buying stocks.

How do I buy shares of Teladoc Health?

Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teladoc Health's stock price today?

One share of TDOC stock can currently be purchased for approximately $246.74.

How big of a company is Teladoc Health?

Teladoc Health has a market capitalization of $35.77 billion and generates $553.31 million in revenue each year. The health services provider earns $-98,860,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Teladoc Health employs 2,400 workers across the globe.

What is Teladoc Health's official website?

The official website for Teladoc Health is www.teladochealth.com.

How can I contact Teladoc Health?

Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here